Groot M T, Boeken Kruger C G G, Pelger R C M, Uyl-de Groot C A
Institute for Medical Technology Assessment, Erasmus University Rotterdam, PO Box 1738, Room L3-105, 3000 DR Rotterdam, The Netherlands.
Eur Urol. 2003 Mar;43(3):226-32. doi: 10.1016/s0302-2838(03)00007-1.
To quantify medical costs associated with bone metastases in patients with prostate cancer. Bone metastases in patients with prostate cancer are associated with considerable morbidity, negatively impact quality of life, and can add substantially to medical costs, given a median survival of 30-35 months from diagnosis of bone metastases.
A retrospective cost analysis from both a community and university hospital in The Netherlands was conducted. Twenty-eight patient records (14 from each hospital) were investigated to assess the impact of skeletal-related events (SREs), including fractures, spinal cord compression, and radiotherapy, on total direct medical costs and cost of hospitalization. Costs are given in EUROS (Euros).
The average total cost of treatment was Euros 13,051 per patient over the 24-month follow-up period, which includes an average cost of Euros 6973 per patient to treat SREs. Treatment of SREs more than doubled total treatment costs. Patients in this analysis experienced, on average, one SRE per year, and the cost of SREs varied from Euros 1187 to Euros 40,948.
Occurrence of SREs contributes significantly to the cost of care for patients with advanced prostate cancer. These data suggest that bisphosphonates, which can reduce pain and SREs, may reduce healthcare costs.
量化前列腺癌患者骨转移相关的医疗费用。前列腺癌患者的骨转移与相当高的发病率相关，对生活质量有负面影响，并且鉴于从骨转移诊断起的中位生存期为30 - 35个月，会大幅增加医疗费用。
对荷兰一家社区医院和一家大学医院进行了回顾性成本分析。调查了28份患者记录（每家医院14份），以评估骨骼相关事件（SREs），包括骨折、脊髓压迫和放疗，对总直接医疗费用和住院费用的影响。费用以欧元（€）为单位给出。
在24个月的随访期内，每位患者的平均总治疗费用为13,051欧元，其中包括每位患者治疗SREs的平均费用为6973欧元。SREs的治疗使总治疗费用增加了一倍多。该分析中的患者平均每年经历一次SREs，SREs的费用从1187欧元到40,948欧元不等。
SREs的发生对晚期前列腺癌患者的护理成本有显著贡献。这些数据表明，可减轻疼痛和SREs的双膦酸盐可能会降低医疗保健成本。
